Artelo Biosciences, Inc. Share Price & Technical Analysis
ARTL · $1.71 (+43.70%)
Healthcare / Biotechnology
$1.71
+43.70%
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocr…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-50% return in May, 3% avg return in past 3 year May month.
17% return in 2026, -48% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 28% | -27% | 117% | -51% | -50% | – | – | – | – | – | – | – | 17% |
| 25 | 13% | -11% | -18% | 14% | 5% | 96% | 7% | -23% | -46% | -32% | -43% | -30% | -69% |
| 24 | 0% | 11% | -3% | -9% | -1% | -1% | 2% | -3% | -11% | 6% | -10% | -2% | -20% |
| 23 | 8% | -11% | -19% | -29% | 6% | 11% | -1% | -1% | -21% | -16% | 13% | 3% | -57% |
| 22 | -20% | -10% | 15% | -15% | -11% | -7% | 8% | -29% | -10% | -16% | -16% | 7% | -103% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.24M
P/E ratio
—
52W high
$85.80
52W low
$1.19
Volume
2,37,86,763
Beta
0.05
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Artelo Biosciences, Inc. share price today?
- Artelo Biosciences, Inc. (ARTL) last traded around $1.71 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ARTL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ARTL. Download the app for real-time alerts.
- How can I analyze Artelo Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.